Keith D. Greenfield
Founder at Dover Group, Inc.
Profile
Keith D.
Greenfield is a Director and Executive VP-Corporate Development at IQuum, Inc. which he founded in 1998.
He is also a Director and Executive VP-Business Development at AZTherapies, Inc. since 2014.
Additionally, he holds Director positions at Sight Code, Inc., Zebra Pharmaceuticals, Inc., NanoTomer, Inc., PhageNova Bio, Inc., and Xylyx Bio, Inc. Mr. Greenfield is also the founder of Dover Group, Inc.
Keith D. Greenfield active positions
Companies | Position | Start |
---|---|---|
Dover Group, Inc. | Founder | - |
Zebra Pharmaceuticals, Inc. | Director/Board Member | - |
Sight Code, Inc. | Director/Board Member | - |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Director/Board Member | 01/08/2014 |
NanoTomer, Inc.
NanoTomer, Inc. Miscellaneous Commercial ServicesCommercial Services NanoTomer, Inc. provides bio technology services. The company is headquartered in Boston, MA. | Director/Board Member | - |
Xylyx Bio, Inc.
Xylyx Bio, Inc. Pharmaceuticals: MajorHealth Technology Xylyx Bio, Inc. provides drug discovery and development services for patients. The company is based in Brooklyn, NY. The company was founded in 2016 by Gordana Vunjak-Novakovic, John D. O'Neill. The CEO is Andrea Nye. | Director/Board Member | - |
PhageNova Bio, Inc.
PhageNova Bio, Inc. BiotechnologyHealth Technology PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin. | Director/Board Member | - |
Former positions of Keith D. Greenfield
Companies | Position | End |
---|---|---|
IQuum, Inc.
IQuum, Inc. Pharmaceuticals: MajorHealth Technology IQuum, Inc. designs and develops biological molecular diagnostics products. It develops lab-in-a-tube technology, a novel biological sample testing platform which provides revolutionary benefits to a broad cross section of the bioassay market. The firm''s proprietary technology enables the non-specialized personnel to perform more sophisticated biological sample testing in any setting with greater speed. The company was founded by Shuqi Chen and Keith Greenfield in 1998 and is headquartered in Marlborough, MA. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 8 |
---|---|
Dover Group, Inc. | |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Health Technology |
IQuum, Inc.
IQuum, Inc. Pharmaceuticals: MajorHealth Technology IQuum, Inc. designs and develops biological molecular diagnostics products. It develops lab-in-a-tube technology, a novel biological sample testing platform which provides revolutionary benefits to a broad cross section of the bioassay market. The firm''s proprietary technology enables the non-specialized personnel to perform more sophisticated biological sample testing in any setting with greater speed. The company was founded by Shuqi Chen and Keith Greenfield in 1998 and is headquartered in Marlborough, MA. | Health Technology |
Sight Code, Inc. | |
Zebra Pharmaceuticals, Inc. | |
NanoTomer, Inc.
NanoTomer, Inc. Miscellaneous Commercial ServicesCommercial Services NanoTomer, Inc. provides bio technology services. The company is headquartered in Boston, MA. | Commercial Services |
PhageNova Bio, Inc.
PhageNova Bio, Inc. BiotechnologyHealth Technology PhageNova Bio, Inc. is a biotechnology company that is developing a modular, bacteriophage-based platform for targeted gene expression in cancer, vaccination, and molecular imaging. PhageNova Bio is based in Scarsdale, NY. The company's lead cancer construct is designed to selectively target tumor-associated blood vessels and tumor cells, resulting in the expression of TNF-?, an anti-tumor agent, specifically and exclusively in tumors. The company has extensively validated tumor targeting and selective gene expression capabilities, and therapeutic efficacy was observed in the absence of dose-limiting toxicity in multiple species and several tumor models. The company was founded by Renata Pasqualini, Wadih Arap, Steven K. Libutti, Juri G. Gelovani, and the CEO is Jason A. Rifkin. | Health Technology |
Xylyx Bio, Inc.
Xylyx Bio, Inc. Pharmaceuticals: MajorHealth Technology Xylyx Bio, Inc. provides drug discovery and development services for patients. The company is based in Brooklyn, NY. The company was founded in 2016 by Gordana Vunjak-Novakovic, John D. O'Neill. The CEO is Andrea Nye. | Health Technology |
- Stock Market
- Insiders
- Keith D. Greenfield